Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 8/20 | 0.49 |
| ▸ | NPC1 | O15118 | 4/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.46 |
| ▸ | HPGD | P15428 | 5/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22445612 | 1.00 | RAB9A (0.49) | RAB9ANPC1POLBALDH1A1HPGD | |
| SCHEMBL22445611 | 1.00 | RAB9A (0.49) | RAB9ANPC1POLBALDH1A1HPGD | |
| SCHEMBL22461004 | 0.84 | RAB9A (0.44) | RAB9ANPC1POLBALDH1A1HPGD | |
| SCHEMBL11796588 | 0.79 | SMN1; SMN2 (0.59) | RAB9ANPC1POLBALDH1A1HPGD | |
| SCHEMBL11796584 | 0.79 | SMN1; SMN2 (0.59) | RAB9ANPC1POLBALDH1A1HPGD | |
| SCHEMBL2720009 | 0.77 | TRPM8 (0.69) | NPC1ALDH1A1L3MBTL1HTT | |
| SCHEMBL2720006 | 0.77 | TRPM8 (0.69) | NPC1ALDH1A1L3MBTL1HTT | |
| SCHEMBL13287300 | 0.75 | IAPP (0.60) | RAB9AALDH1A1SMN1; SMN2LMNAKDM4E | |
| SCHEMBL3362442 | 0.75 | IAPP (0.60) | RAB9AALDH1A1SMN1; SMN2LMNAKDM4E | |
| SCHEMBL27832643 | 0.75 | IAPP (0.60) | RAB9AALDH1A1SMN1; SMN2LMNAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220177488-A1 | SUMO INHIBITOR COMPOUNDS AND USES THEREOF | CIT THERAPEUTICS LLC | 2022-06-09 | — | — | US | disclosed |
| WO-2020191151-A1 | SUMO INHIBITOR COMPOUNDS AND USES THEREOF | ONCOVALENT THERAPEUTICS INC. (US) | 2020-09-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220177488-A1 | SUMO INHIBITOR COMPOUNDS AND USES THEREOF | SUMO1, SUMO2, SUMO3 | RAB9A 2154/4885NPC1 2611/4885POLB 2331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.